JP2025118607A5 - - Google Patents

Info

Publication number
JP2025118607A5
JP2025118607A5 JP2025060888A JP2025060888A JP2025118607A5 JP 2025118607 A5 JP2025118607 A5 JP 2025118607A5 JP 2025060888 A JP2025060888 A JP 2025060888A JP 2025060888 A JP2025060888 A JP 2025060888A JP 2025118607 A5 JP2025118607 A5 JP 2025118607A5
Authority
JP
Japan
Prior art keywords
release formulation
sustained release
polypeptide
sustained
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025060888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025118607A (ja
Filing date
Publication date
Priority claimed from JP2021562971A external-priority patent/JP7726791B2/ja
Application filed filed Critical
Publication of JP2025118607A publication Critical patent/JP2025118607A/ja
Publication of JP2025118607A5 publication Critical patent/JP2025118607A5/ja
Pending legal-status Critical Current

Links

JP2025060888A 2019-04-24 2025-04-02 補体活性を調節するための組成物及び方法 Pending JP2025118607A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962837978P 2019-04-24 2019-04-24
US62/837,978 2019-04-24
US201962947183P 2019-12-12 2019-12-12
US201962947188P 2019-12-12 2019-12-12
US62/947,188 2019-12-12
US62/947,183 2019-12-12
JP2021562971A JP7726791B2 (ja) 2019-04-24 2020-04-24 補体活性を調節するための組成物及び方法
PCT/US2020/029733 WO2020219822A1 (en) 2019-04-24 2020-04-24 Compositions and methods for modulating complement activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021562971A Division JP7726791B2 (ja) 2019-04-24 2020-04-24 補体活性を調節するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2025118607A JP2025118607A (ja) 2025-08-13
JP2025118607A5 true JP2025118607A5 (cg-RX-API-DMAC10.html) 2025-11-11

Family

ID=70977557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562971A Active JP7726791B2 (ja) 2019-04-24 2020-04-24 補体活性を調節するための組成物及び方法
JP2025060888A Pending JP2025118607A (ja) 2019-04-24 2025-04-02 補体活性を調節するための組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021562971A Active JP7726791B2 (ja) 2019-04-24 2020-04-24 補体活性を調節するための組成物及び方法

Country Status (13)

Country Link
US (2) US20220211799A1 (cg-RX-API-DMAC10.html)
EP (1) EP3958842B1 (cg-RX-API-DMAC10.html)
JP (2) JP7726791B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220004039A (cg-RX-API-DMAC10.html)
CN (1) CN113710230A (cg-RX-API-DMAC10.html)
AU (1) AU2020261059A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021017820A2 (cg-RX-API-DMAC10.html)
CA (1) CA3137895A1 (cg-RX-API-DMAC10.html)
IL (1) IL287079A (cg-RX-API-DMAC10.html)
MX (1) MX2021013010A (cg-RX-API-DMAC10.html)
SG (1) SG11202109837SA (cg-RX-API-DMAC10.html)
TW (1) TW202106290A (cg-RX-API-DMAC10.html)
WO (1) WO2020219822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
SMT202100688T1 (it) 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
KR20260070290A (ko) 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
SG11202103972SA (en) * 2018-10-22 2021-05-28 Ra Pharmaceuticals Inc Neurological disease treatment with zilucoplan
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241139A (zh) * 1996-12-20 2000-01-12 武田药品工业株式会社 生产缓释制剂的方法
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
EP2266606B1 (en) 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CN1289066C (zh) * 2003-09-18 2006-12-13 中国人民解放军第二军医大学 胰高血糖素样肽-1缓释微球制剂及其用途
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
CN101374554A (zh) 2005-09-27 2009-02-25 埃弗拉特生物聚合物有限公司 胶凝疏水性可注射聚合物组合物
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10,顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
RU2009144142A (ru) 2007-04-30 2011-06-10 Алькон Рисерч, Лтд. (Us) Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента
AU2008262048B2 (en) 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
JP5473925B2 (ja) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
EP3089742A4 (en) * 2013-12-31 2017-08-02 Heron Therapeutics, Inc. Polymer-based compositions for extended release of proteins
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
WO2016138520A1 (en) 2015-02-27 2016-09-01 The Johns Hopkins University Assay to diagnose and treat disorders of the alternative pathway of complement activation
KR20260070290A (ko) * 2015-12-16 2026-05-18 유씨비 홀딩스 인코포레이티드 보체 활성의 조절인자
US20170333304A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel Particles, Compositions, and Methods
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
DK3411400T3 (da) * 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet

Similar Documents

Publication Publication Date Title
JP2022530042A5 (cg-RX-API-DMAC10.html)
AU2003238862B9 (en) Formulations for amylin agonist peptides
TWI241911B (en) Sustained release ranolazine formulations
JP2637981B2 (ja) 吸収制御薬剤組成物
KR102662530B1 (ko) 양극성 용매에서 안정한 치료 제형들의 제조방법.
WO2006105501A2 (en) Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
WO2003103637A2 (en) Modified release, multiple unit drug delivery systems
CZ234898A3 (cs) Zdokonalené koncentrované injekční a infusní roztoky pro intravazální použití
MX2008016254A (es) Uso de agonistas del receptor de adenosina a2a en el tratamiento de isquemia.
CN102138912A (zh) 硝苯地平渗透泵控释片及其制备工艺
JP2017534604A5 (cg-RX-API-DMAC10.html)
WO2015123997A1 (zh) 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法
CN113018277A (zh) 注射用缓释制剂及其制备方法
JP2022527276A5 (cg-RX-API-DMAC10.html)
KR20130126253A (ko) 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
Galanello Iron chelation: new therapies
CN108338976A (zh) 一种硝苯地平双层渗透泵片及其制备方法
US20170312297A1 (en) Long Acting Pharmaceutical Compositions For Hepatitis C
CN102580056B (zh) 一种含抗利尿成分的缓释注射剂及其制备方法
CN1969814B (zh) 褪黑素鼻腔给药制剂
RU2678324C2 (ru) Составы лоразепама с замедленным высвобождением
JP7518149B2 (ja) 高濃度インスリン製剤
US20040092480A1 (en) Medicinal composition
KR20250103637A (ko) 비양성자성 극성 용매를 사용한 서방형 주사용 제형
CA2685214A1 (en) Improved controlled release oral dosage form